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Decades of research have increased our understanding of the
role and interplay between serum cholesterol, inﬂammation,
and oxidative stress in the pathogenesis of atherosclerosis (1).
Uptake and retention of low-density lipoprotein (LDL) by
macrophages in the intima is dependent on adhesion mole-
cules and inﬂammatory cytokines and ampliﬁed by oxidative
stress. This hostile environment is toxic to endothelial and
smooth muscle cells, which further hampers vascular ho-
meostasis. These interrelated steps provide potentially fruitful
therapeutic targets for the prevention and treatment of
atherosclerosis.
See page 1446
Heat shock proteins (HSPs) may lie at this juncture, as
they modulate immune responses, cytotoxicity, and
oxidative stress. This class of proteins was discovered in
the 1960s and initially described as inducing transient
resistance to cell death in response to increasing temper-
ature (2). Subsequently, subtypes were discovered and
found to play unique biological roles as molecular chap-
erones, with some shown to protect cells from apoptosis
induced by ischemia and energy depletion (reviewed by
Kregel [3]).
HSP27 was found in the 1980s to play a predominantly
antiapoptotic role (4) via modulating cytochrome C–
mediated cytosolic activation of caspases (5). Its potential
role in atherosclerosis subsequently emerged from basic
investigations and studies of human vascular tissues.
Martin-Ventura et al. (6) demonstrated that high levels of
HSP27 were present in healthy vessels and decreased in
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with healthy controls. A follow-up in vitro study suggested
that HSP27 may induce plaque stability through modula-
tion of plasmin and other mediators of apoptosis (7).
Moreover, an electrophoretic analysis of human carotid
endarterectomy specimens demonstrated that HSP27 was
increased in the normal portions of the vessel compared
with nearby atherosclerotic plaques, implying that the
presence and/or production of HSP27 confers plaque
stability (8).
Sex-speciﬁc atheroprotective effects of HSP27 were
described by Rayner et al. (9), who demonstrated in an
ApoE knockout mouse model of atherosclerosis that fe-
male mice with transgenic HSP27 overexpression exhibited
reduced atherosclerotic plaque area, concomitant with
increased circulating HSP27 levels. Mechanistic studies
demonstrated that estrogen receptor beta stimulation
induces the expression and release of HSP27 in macro-
phages, which prevent the uptake of modiﬁed LDL
and inﬂammatory cytokine release (10). Although these
studies in genetically modiﬁed mouse models are infor-
mative, investigations using approaches that are more
analogous to clinical practice are required to advance the
ﬁeld toward the bedside.
In the present study, Seibert et al. (11) advance our
understanding of both the clinical and basic science
implications of HSP27’s role in atherosclerosis. The
authors obtained data prospectively from a human cohort
demonstrating that decreased serum HSP27 correlates with
the presence of anatomic coronary artery disease and the
incidence of major adverse cardiac events (MACE). The
ﬁndings regarding the former are consistent with published
data showing that serum HSP27 levels are higher in
healthy subjects compared with those with carotid artery
stenosis (6). Regarding the latter, data are conﬂicting, with
1 previous study reporting an increase in serum HSP27 in
patients with acute coronary syndrome (8), and a prospec-
tive study (in women) failing to ﬁnd a correlation between
increased serum levels of HSP27 and reduced incidence of
MACE (12).
The authors further report that patients with higher
levels of HSP27 (dichotomously separated) are more
likely to be female, which is also consistent with published
data demonstrating that HSP27 is linked to circulating
estrogen levels, although it should be emphasized that the
subgroup of patients with higher levels of HSP27 also
appears to be generally healthier (younger with a lower
prevalence of comorbidities). Nevertheless, the study is
intriguing and provides evidence of the feasibility of
measuring HSP27 in the serum and its potential use as
a novel biomarker of cardiovascular disease. It does not,
however, demonstrate the potential for HSP27 to identify
high-risk patients independently of other risk factors.
This and other issues would need to be resolved to
determine the overall utility of HSP27 as a biomarker for
cardiovascular risk.
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1456The authors proceed to present data conﬁrming a modu-
latory role for HSP27 in the development of atherosclerosis
in a mouse model. They ﬁrst demonstrate that over-
expression of HSP27 in bone marrow–derived cells is
sufﬁcient to elicit atheroprotection, consistent with the
macrophage mechanism of action proposed in previous
publications by this group. Histology of the atherosclerotic
plaque in mice with bone marrow–derived HSP27 over-
expression demonstrated reduced plaque size and lesional
apoptosis. As a next step toward clinical translation, the
authors tested whether recombinant HSP (rHSP27) can
effectively modulate the progression of atherosclerosis. Mice
treated with rHSP27 exhibited reduction in plaque forma-
tion. Interestingly, mice treated with exogenous rHSP27,
but not those with bone marrow–derived HSP27 over-
expression, exhibited lower serum cholesterol levels,
implying that rHSP27 may also modulate atherosclerosis by
favorably affecting the lipid proﬁle.
The enthusiasm for HSP27 as a potential therapeutic
target in atherosclerosis should be tempered by our lack of
knowledge of the precise mechanism of action of HSP27,
whether its efﬁcacy is sex speciﬁc, and how cholesterol levels
might be affected by the recombinant protein. Moreover,
administration of the recombinant protein could lead to the
development of antibodies that over time might hamper
therapeutic efﬁcacy. Furthermore, HSP27 may affect the
development and/or progression of estrogen-dependent
cancers because it has been associated with both favorable
and adverse prognosis in estrogen-positive breast cancers
and the degree of tumor differentiation in endometrial
carcinomas (13). Moreover, blockade of HSP27 has been
used to interrupt the growth of other types of cancers,
suggesting that rHSP27 could have opposite effects (14).
Even if data continue to accumulate to support beneﬁcial
effects of HSP27 in atherosclerosis, extensive preclinical
studies would be required to document an acceptable safety
proﬁle.
In summary, Seibert et al. (11) have advanced our
understanding of HSP27 as a putative biomarker and
therapeutic target in atherosclerosis. The authors are to be
congratulated for their work, which answers many
important questions. As to be expected, however, their
study also raises many new questions that will need to be
addressed to continue advancing this area of research to
the bedside.Reprint requests and correspondence: Dr. Neal L. Weintraub,
Division of Cardiovascular Diseases, Department of Internal
Medicine, University of Cincinnati College of Medicine, 231
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